Floor J. Backes, MD, discusses the results from a phase I trial investigating the combination of lenvatinib (Lenvima) and paclitaxel in patients with recurrent ovarian, fallopian tube, or peritoneal cancers.
Floor J. Backes, MD, associate professor at The Ohio State University Comprehensive Cancer Center, discussesthe results from a phase I trialinvestigating the combination of lenvatinib (Lenvima) and paclitaxel in patients with recurrent ovarian, fallopian tube, or peritoneal cancers.
The primary goal of the study was to find a recommended phase II dose. The trial established an 80 mg weekly of paclitaxel and a daily dose of lenvatinib at 60 mg, says Backes. The combination appeared safe and tolerable in these patients.
Avutometinib/Defactinib Leads to Positive Response, Survival Data in Ovarian Cancer
October 18th 2024The completion of a new drug application for the combination of avutometinib and defactinib in KRAS-mutant ovarian cancer is expected to be finalized with the FDA by the end of the month.
Read More